Sat, Jul 12, 2014, 4:08 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Oncothyreon Inc Message Board

  • messaaaa messaaaa Aug 9, 2013 12:05 PM Flag

    Arry 380..good move for ONTY

    ARRY-380 - New oncology collaboration with Oncothyreon Inc.
    In May 2013, Array and Oncothyreon announced a collaboration to develop and commercialize ARRY-380, an orally active, reversible and selective small-molecule HER2 inhibitor. Oncothyreon paid Array an upfront fee of $10 million upon initiation of the collaboration. Under the agreement, Oncothyreon is funding the clinical development of ARRY-380 through a defined set of combination proof-of-concept trials in patients with metastatic breast cancer, including patients with brain metastases. Array and Oncothyreon intend to jointly conduct Phase 3 development supported by the proof-of-concept studies. Array is responsible for worldwide commercialization of the product. Oncothyreon has a co-promotion right in the U.S., and the two companies will share the cost of U.S. commercialization, including any profit, equally. Outside of the U.S., Oncothyreon will receive a double-digit royalty on net sales.

 
ONTY
2.66-0.07(-2.56%)Jul 11 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.